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Abstract
Background: Treatment complexity rises in line with the number of drugs, single doses, and administration
methods, thereby threatening patient adherence. Patients with multimorbidity often need flexible, individualised
treatment regimens, but alterations during the course of treatment may further increase complexity. The objective
of our study was to explore medication changes in older patients with multimorbidity and polypharmacy in general
practice.
Methods: We retrospectively analysed data from the cluster-randomised PRIMUM trial (PRIoritisation of MUltimedication
in Multimorbidity) conducted in 72 general practices. We developed an algorithm for active pharmaceutical ingredients
(API), strength, dosage, and administration method to assess changes in physician-reported medication data during two
intervals (baseline to six-months: Δ1; six- to nine-months: Δ2), analysed them descriptively at prescription and patient
levels, and checked for intervention effects.
Results: Of 502 patients (median age 72 years, 52% female), 464 completed the study. Changes occurred in 98.6% of
patients (changes were 19% more likely in the intervention group): API changes during Δ1 and Δ2 occurred in 414 (82.5%)
and 338 (67.3%) of patients, dosage alterations in 372 (74.1%) and 296 (59.2%), and changes in API strength in 158 (31.5%)
and 138 (27.5%) respectively. Administration method changed in 79 (16%) of patients in both Δ1 and Δ2. Simvastatin,
metformin and aspirin were most frequently subject to alterations.
Conclusion: Medication regimens in older patients with multimorbidity and polypharmacy changed frequently. These are
mostly due to discontinuations and dosage alterations, followed by additions and restarts. These findings cast doubt on
the effectiveness of cross-sectional assessments of medication and support longitudinal assessments where possible.
Trial registration.: 1. Prospective registration: Trial registration number: NCT01171339; Name of registry: ClinicalTrials.gov;
Date of registration: July 27, 2010; Date of enrolment of the first participant to the trial: August 12, 2010.
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Background
General practitioners (GPs) are confronted with older
patients with multiple chronic diseases in up to 80%
of their consultations, i.e. patients with multimorbi-
dity [1, 2]. Multimorbidity is strongly associated with
polypharmacy, most commonly defined as the regular
use of five or more drugs [3]. Polypharmacy increases
the risk of inappropriate prescriptions from drug
misuse (e.g., drug-drug interactions, drug-disease interac-
tions, and inappropriate dosages) and drug selection (over-
use and underuse), and may result in hospitalisations, falls
and related injuries, decreased quality of life, cognitive and
physical dysfunction, loss of autonomy, and increased mor-
tality as well as preventable health care spending [4–12].
The indiscriminate use of disease-specific treatment
guidelines for patients suffering from multimorbidity and
uncoordinated treatment by multiple physicians are drivers
of polypharmacy and lead to complex medication regimens
involving multiple drugs [13–15]. However, medication ad-
herence in patients is inversely correlated with the number
of drugs and the complexity of the medication regimen
[16]. The higher the number of drugs and doses per day,
pills per dosage, different administration methods and spe-
cific recommendations related to drug use, such as dietary
recommendations, the greater is treatment complexity and
burden, and the patient’s inability to cope [14, 17, 18].
Medication changes over time may further increase treat-
ment complexity because patients develop routines that
enable them to manage their daily medication regimens,
and adjusting them can be very troublesome for the chron-
ically ill [19, 20]. On the other hand, medication changes
often reflect patients’ preferences, particularly when condi-
tions are symptomatic. The assessment of patient priorities
and shared decision making when evaluating and changing
medication in older patients with multimorbidity have been
identified as important [21–23]. From the physician’s
perspective, indications that an established drug regimen
should be changed may be related to the development of
new symptoms or worsening existing conditions, suspected
medication-related adverse effects and because the treat-
ment does not benefit the patient to the degree expected
[24]. Particularly in patients with multimorbidity, evidence
on effective treatment strategies is often lacking, and fle-
xible and individualised pharmacotherapy is needed to
meet their needs and preferences. As a result, GPs often
rely on “hunches or best guesses” when deciding how to
treat their patients [25]. Although, GPs frequently prefer
to maintain the status quo once a patient appears to be
stable [25], and are frequently reluctant to make changes
to complex regimes, even if a potential problem has been
identified [26, 27], their “hunches and best guesses” may
lead to constant adaptation and frequent medication
changes. Moreover, profound changes in a medication
regimen are frequently made when patients are
hospitalised and immediately thereafter. Newly introduced
medication has not reached its steady state at discharge
because inpatient care is frequently shorter than four to
five half-lives of prescribed drugs, so that effectiveness
and side-effects have not be properly assessed in hos-
pital [28–30]. As variable discount contracts between
pharmaceutical companies and statutory health in-
surers dictate the use of generic medicaments in
Germany, changes may also be made in an attempt to
reduce costs, rather than for medical reasons.
Available consultation times apparently also influence pre-
scribing behaviours. An average consultation time of less
than seven minutes has been shown to be related to
higher prescribing rates, whereas a consultation time of
nine minutes or longer is associated with lower rates [31].
While all these determinants and consequences of pre-
scribing behaviour and regimen complexity have been in-
vestigated in numerous cross-sectional studies, much less is
known about how often medication regimens are changed
over time, and what kind of changes older patients with
multimorbidity and polypharmacy are faced with and have
to manage. Improved insights into the number and nature
of medication changes in this population may help stra-
tegies to be developed that avoid unnecessary medication
changes. The goal of this study was therefore to explore
changes in prescribed medication in older patients with
multimorbidity and polypharmacy in primary care over a
nine-month period.
Methods
Setting and population
We retrospectively assessed data from the pragmatic
cluster-randomised controlled PRIMUM trial (PRIoritisa-
tion of MUltimedication in Multimorbidity) with the
general practice as the unit of randomisation. The methods
used in the PRIMUM trial are reported in detail elsewhere
[32]. Briefly, the PRIMUM study evaluated the effectiveness
of a complex intervention in improving medication appro-
priateness in comparison to usual care. The complex inter-
vention consisted of four elements: the practice-based
health care assistant (1) conducted a checklist-based inter-
view with patients on medication-related problems and (2)
reconciled their medications. (3) Assisted by a compu-
terised decision-support system, the general practitioner
optimised medication, and (4) discussed recommended
changes with patients and adjusted medication regimens
accordingly [32, 33]. Health care assistants in Germany re-
ceive less training than nurses, are comparable to certified
medical assistants in the USA [34]. However, they have
repeatedly and successfully carried out chronic care inter-
ventions that involve, for example, surveying patients by
following protocols with fixed interview questions for con-
ditions such as major depression, osteoarthritis and chronic
heart failure, under the supervision of GPs [35–38].
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Control practices continued with usual care. In usual
care in Germany, patients regularly consult their GPs to
discuss health problems, but, as GPs are not acting as ‘gate
keepers’, may also contact ambulatory care specialists dir-
ectly. Regular medication reviews were not conducted at
the time of the study and health care for patients with
chronic diseases has been characterized as fragmented
and uncoordinated [39]. The presence of multiple condi-
tions may have worsened the situation [40].
In total, 72 general practices located in the German
state of Hesse participated in the PRIMUM trial. Of
these practices, a random sample of 505 patients aged
≥60 years, with ≥3 chronic conditions for which they
were treated with ≥5 drugs with systemic effects was in-
cluded in the study. Patients were also required to be
able to participate in telephone interviews, complete
written questionnaires and provide written informed
consent. Patients with cognitive impairment (Mini Mental
State Exam < 26) and a life expectancy under 12 months
were excluded. Patients’ degree of multimorbidity was
assessed at baseline using the Cumulative Illness Rating
Scale (CIRS) [41, 42].
Measurement of medication changes
We assessed the number of changes to drugs, dosages
and administration methods over a nine-month follow-
up period. Data on prescribed medicines (active pharma-
ceutical ingredient (API) or trade name, dosage, and
dosage form) were reported at baseline (T0), as well as
six (T1), and nine (T2) months later. The first interval
(Δ1) was between baseline and the 6-month follow-up and
the second interval (Δ2) between the 6- and 9-month
follow-ups.
At study visits, the attending health care assistant at the
practice entered data on each participating patient into a
paper-based case report form (CRF) and the GP checked
the documentation before the CRF was sent to the study
centre. At the study centre, a study assistant entered CRF
data into an Access™ database where it was checked by an-
other assistant. Based on an online database (“Gelbe
Liste™”), an assistant coded the drugs according to API,
strength, dosage form and a standardised package size of
“N2” (generally containing the quantity of the drug required
for 30 days of treatment) using the National Drug Code
(PZN). PZN codes were converted into ATC codes, APIs,
strengths, and dosage form automatically. Converted infor-
mation was cross-checked against reported information for
validation.
To explore medication changes in terms of medication
usage, we adapted the algorithm suggested by Lam and
co-workers [20]. We differentiated between changes
(1) relating to API, (2) the strength of the API
(amount of API per application unit e.g. tablet) (3)
the dosage (the number of application units that
make up the medication regimen) and (4) the admin-
istration method, reflecting the four main dimensions
of a drug prescription (see Fig. 1).
API changes included the addition and discontinuation
of drugs, restarts and intraclass-substitutions. Additions
were medications that were present at one of the
follow-up visits but were not reported before. Discontin-
uations referred to drugs that were mentioned previously
but not reported at a later study visit. Restarts were
drugs, which were discontinued between T0 and T1 but
re-prescribed during the second interval (Δ2). Intraclass
substitutions were substitutions of a medicine by
another drug of the same drug class, as reflected in the
five-digit ATC-code. The strength of the API was chan-
ged if a higher or lower amount of the same API per
unit of the medication was reported at one study visit
compared to a previous one. The dosage was changed if
the total daily dose (the amount of API per day) was in-
creased or decreased, the application interval prolonged
or shortened, and/or the application time altered be-
tween visits. The dosage was additionally modified when
tablet splitting started or stopped. We measured changes
to the administration method in accordance with the
Medication Regimen Complexity Index (MRCI) [17].
CM assigned each of the 299 pharmaceutical dosage
forms defined by the European Directorate for the
Quality of Medicines & Health Care (EDQM) that were on
the market at the time of the study to one of the 14 dosage
forms used in the MRCI (immediate and extended release
tablets, capsules, dragées, drops, liquids, effervescent
tablets, sprays, ointments, plasters, metered-dose inhalers,
syringes, suppositories, others). The classification was
cross-checked by the clinical pharmacologist.
For medications with more than one active ingredient
(combination drugs), we concentrated on changes in the
active ingredient for the main indication of the drug.
The main indication is represented by the three-digit
ATC code describing the main therapeutic group for the
particular medication. Changes in other active ingredients
of combination drugs were not taken into consideration.
FvB reviewed the medication changes of study partici-
pants. The algorithm was then applied electronically by
MSH. Any disagreement was checked and corrected and
the algorithm was refined where necessary.
Statistical analysis
Data were analysed descriptively on a patient level and
on the level of prescriptions using STATA version SE 13.
For this purpose, we collected prescription data on each
patient from the physicians at each one of the three
study visits (T0, T1, T2). Changes from one study visit
to the next were assessed for both intervals (Δ1, and Δ2).
A longitudinal prescription trajectory was developed for
the prescriptions and study visits, with the patient’s first
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specific drug prescription as the reference (called refe-
rence prescriptions in the remainder of the article). The
results are presented in absolute and relative numbers
(percentages), means and standard deviations, or median
and interquartile ranges (IQR).
The test for equal proportions was used to analyse
changes and derive rate ratios between intervention and
control groups. The Spearman correlation coefficient
was used to analyse the relationship between the abso-
lute numbers of medication changes in both time
intervals.
The R software/environment version 3.3.2 (R Founda-
tion for Statistical Computing, Vienna, Austria, 2016)
was used for multivariate analyses and, in particular, to
estimate and control for the intervention effect.
Accounting for the clustering structure within GPs, a
generalised linear mixed model was applied by the pack-
age glmmADMB [43]. Following an exploratory assess-
ment of multi-collinearity and missing data patterns, the
model was parameterised according to the independent
variables intervention status, age, sex and respective
changes in number of previous hospital visits at baseline,
and the Cumulative Illness Rating Scale (CIRS) summary
score between the follow-up visit and baseline. When
modelling total prescription changes between study visits
(T0, T1, T2), a negative binomial distribution provided
the best fit to appropriately address overdispersion.
Intra-cluster correlation (ICC) was obtained from the
model in accordance with Aly and co-workers [44]. All
tests were two-tailed. 95% confidence intervals (CI) were
calculated, and P values < 0.05 were considered statisti-
cally significant.
Results
Of the 72 participating GP’s, 41 worked in single-handed
practices, and 31 in group practices. Their median age was
50 years (IQR 46.5–56), the majority was male (56.9%) and
they had on average 23.5 years clinical experience (IQR
15.75–29).
We included 502 patients in our analyses (three had to
be removed from the PRIMUM study population because
they were younger than 60 at baseline), of whom 464 com-
pleted the study (see additional file 1). Their median age
was 72 years (IQR 67–77), 52% of them were female (for
patient’ characteristics in intervention and control group,
see Table 1). At baseline and the two follow-up visits, the
sum of all prescriptions was 11,719 and the total number of
reference prescriptions was 4999. The most commonly pre-
scribed therapeutic subgroups were agents acting on the
renin-angiotensin system (ATC code C09: n = 514 prescrip-
tions accounting for 10% of reference prescriptions), drugs
used in diabetes (A10: n = 468, 9%), antithrombotic agents
(B01: n = 409, 8%), drugs acting on the lipid metabolism
(C10: n = 355, 7%) and beta blocking agents (C07: 352, 7%).
See also Table 2.
Medication changes at patient level
Cumulatively, 99% of patients showed at least one medi-
cation change over the nine-month period with a me-
dian of 9.5 (IQR 6–15) changes per patient. The
maximum of medication changes was 21 (in one patient)
during the six months of Δ1 and 20 (in two patients)
during the three months in Δ2. The mean number of
changes per patient was 6.5 (STD 4.3) in Δ1 and 4.4
(STD 3.9) in Δ2. The total number of drugs per patient
Fig. 1 Medication Changes at Prescribing Level. API: active pharmaceutical ingredient. 1ATC-Code 5 digits. ATC: anatomical therapeutic chemical
classification system. Interval Δ1: baseline to six-month follow-up; interval Δ2: six- to nine-month follow-ups
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remained relatively constant (the median number of pre-
scriptions was 8 at all study visits, while the IQR was 6
to 9 at T0 and T1 and 6 to 10 at T2). (See Fig. 2).
The most frequent changes occurred in the active
ingredient, the subcategories of which were addition,
discontinuation, intraclass substitution and restart (Δ2,
only). The API was changed in 414 (83%) of the patients
during Δ1 and 338 (67%) during Δ2 (in Δ1 and Δ2, the
mean number of API changes per patient were 3.1 and
2.1 respectively). We observed up to eight additions per
patient in both periods. The mean number of added
drugs per patient was 1.3 (STD 1.5) during Δ1 and 0.6
(STD 1.0) during Δ2. Patients had discontinued up to 15
drugs in Δ1 and 16 in Δ2, with a mean number of
de-prescribed drugs per patient of 1.6 (STD 1.9) in Δ1
and 1.7 (STD 2.0) in Δ2.
Changes in the strength of the API occurred in 158
(32%) patients in Δ1 and 138 (28%) patients in Δ2 (in Δ1
and Δ2, mean change per patient was 0.4 (STD 0.65) and
0.3 (STD 0.61) respectively). Dosages were altered in 372
(74%) patients in Δ1 and in 296 (59.2%) patients in Δ2.
The mean number of dosage changes per patient was
2.9 (STD 2.87) and 1.8 (STD 2.21) respectively (Table 3).
There was no statistical correlation between medication
changes in Δ1 and Δ2 with correlation coefficients indica-
ting weak relationships, if any (Spearman correlation coeffi-
cient for overall medication changes between Δ1 and Δ2
was 0.321 and 0.005 between discontinuations in Δ1 and
any changes in Δ2). The multivariate model showed that
more medication changes occurred in the intervention
group. We compared both groups and found 19% more
medication changes in the intervention group (95% CI
[0.3%; 41%], P = 0.0046), which was the only significant
factor in the multiple regression model. It is noteworthy
that an ICC of 0.146 was observed. Univariate analyses
showed that the reduction in the dosage was slightly greater
but significantly so in the intervention group compared to
the control group but no further significant differences in
the various types of medication changes were found
between both groups (Table 3).
Medication changes at prescribing level
The analysis of the medication included N = 4999 reference
prescriptions. In total, we detected N = 5478 cumulative
changes in these reference prescriptions during the
nine-month follow-up. Figure 1 shows the distribution of
changes in reference prescriptions, as determined using our
algorithm. The mean number of changes per reference pre-
scription was 1.09 (STD 1.2). The most frequently changed
drugs in our older study population with multimorbidity
Table 1 Baseline characteristics of patients
Characteristics
(median, IQR)a
Intervention group
(n = 252)
Control group
(n = 250)
Total
(N = 502)
Age 72 (69–77) 72 (66–77) 72
(67–77)
Female sex (n, %) 133 (53%) 129 (52%) 262 (52%)
CIRS sum score 7 (5–11) 7 (4–10) 7 (4–11)
Number of prescriptions 8 (6–10) 8 (6–9) 8 (6–9)
MRCI 24 (17–36) 24 (18–33) 24
(18–34)
CIRS cumulative illness rating scale, MRCI medication regimen
complexity index
aif not stated otherwise
Table 2 Most commonly prescribed medicines
Chemical subgroupb
Most prevalent active
pharmaceutical ingredient (API)c
Absolute and relative frequency
of prescriptionsa (n, %)
Platelet aggregation inhibitors excl.
Heparin (B01AC):
323 (6.5%)
Acetylsalicylic acid (B01AC06) 261 (5.2%)
Beta blocking agents, selective
(C07AB):
297 (5.9%)
Bisoprolol (C07AB07) 135 (2.7%)
Metoprolol (C07AB02) 128 (2.6%)
HMG CoA reductase inhibitors (C10AA) 297 (5.9%)
Simvastatin (C01AA01) 256 (5.1%)
Proton pump inhibitors (A02BC) 231 (4.6%)
Omeprazole (A02BC01) 126 (2.5%)
Pantoprazole (A02BC02) 93 (1.9%)
ACE inhibitors, plain (C09AA) 218 (4.4%)
Ramipril (C09AA05) 139 (2.8%)
Dihydropyridine derivatives (C08CA) 208 (4.2%)
Amlodipine (C08CA01) 148 (3.0%)
Sulfonamides, plain (C03CA) 176 (3.5%)
Torasemide (C03CA04) 133 (2.7%)
Thyroid hormones (H03AA) 159 (3.2%)
Levothyroxine (H03AA01) 119 (2.4%)
Biguanides (A10BA) 131 (2.6%)
Metformin (A10BA02) 131 (2.6%)
Preparations inhibiting uric acid
production (M04AA)
123 (2.5%)
Allopurinol (M04AA01) 120 (2.4%)
Angiotensin II antagonists, plain
(C09CA)
117 (2.3%)
Candesartan (C09CA06) 40 (0.8%)
Low-Ceiling Diuretics, Thiazides, plain
(C03AA)
97 (1.9%)
Hydrochlorothiazide (C03AA03) 97 (1.9%)
Selective beta-2-adrenoreceptor ago-
nists (R03AC)
95 (1.9%)
Salbutamol (R03AC02) 46 (0.9%)
aRelative frequency: absolute numbers of prescriptions with regard to the total
number of reference prescriptions (N = 4999)
baccording to the 4th level, chemical subgroup (5-digit ATC code)
caccording to the 5th level, chemical substance (7-digit ATC code)
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were simvastatin (mostly, a change in the strength of API,
an increase or decrease of dosage, a change in the applica-
tion time and starting or stopping tablet splitting), low dose
aspirin (addition, discontinuation and restart as well as
changes in time of application), metformin (application
interval and time, and decrease in dosage), omeprazole
(intraclass substitution of pantoprazole or esomeprazole)
and ramipril (strength of API and application interval; see
Table 4). Most of the restarts (after previous disconti-
nuation) were seen in low dose aspirin, metoprolol, HCT,
ramipril and diclofenac.
Discussion
Key findings
In our study population of older patients with multimor-
bidity and polypharmacy, more than three quarters of
prescriptions was modified within six months (Δ1) and
another half in the three months thereafter (Δ2). Accor-
ding to our algorithm, changes occurred in all catego-
ries, with changes in API (83%) the most common, and
changes in administration method (16%) the least. The
API was most often changed through discontinuation
(in more than two thirds of the patients at least one drug
was stopped during Δ1 and in almost half the patients
during Δ2). However, our data also showed that at least
one third of previously discontinued drugs were
restarted (we could only measure restarts in the second
period, Δ2). Furthermore, the number of dosage alterations
was high and observed in 82% of patients. Despite such
high levels of prescribing and de-prescribing, the total
number of medications per patient remained remarkably
constant. This finding supports the general view that drug
numbers barely reflect prescription appropriateness
[45, 46]. In order to optimise a patient’s medication, it can
be warranted both to stop (i.e., de-prescribe) unnecessary
drugs and to start taking indicated drugs [47].
On a prescription level, our research revealed that the
most frequent modifications occurred in simvastatin and
low-dose aspirin, which are both drugs that should be
prescribed in relatively fixed doses in the treatment (or
prevention) of chronic conditions. Changes in dosage
were the most frequently observed modifications in both
drugs. In the case of simvastatin, presumed or actual
common side effects (myalgia) [48] may have encou-
raged the treating physician to replace the statin with an
intermittent or pulsed dosing regimen [49], or to slowly
increase doses in highly intolerant patients [50]. Restarts
of metoprolol, ramipril, diuretics or diclofenac may have
been decided when underlying health problems exacer-
bated and precluded a discontinuation or withdrawal
symptoms occurred [51]. The intraclass substitution of
pantoprazole for omeprazole may reflect the reduced
likelihood of drug-drug interactions in pantoprazole
[52]. Other frequent modifications, such as discontinu-
ation or dosage alterations in diuretics or anti-diabetics
are easier to interpret, but the reasons behind changes
were not documented in our study.
Comparison with literature
The basic pattern of medication changes in our study
was consistent with a previous observation study on
older patients with multimorbidity and polypharmacy
which also identified frequent starting, stopping and
dosage changes [20]. However, the proportion of patients
whose medication regimen was modified was higher in
our study than in the previous one, in which additions
were observed in 61%, discontinuations in 58%, dose
changes in 51% and restarts in 21% of patients [20]. The
differences may reflect different study designs and data
collection methods. While we collected primary data
from GPs in a polypharmacy study on medication
optimisation, Lam et al. analysed claims data [20]. In our
analysis, the intervention slightly increased the rate at
which changes were made in the intervention group. In
de-prescribing trials in community-dwelling elderly
patients, 47% [53] and 48% [54] of patients reported at
Fig. 2 Medication Changes at Patient Level. Interval Δ1: baseline to six-month follow-up; interval Δ2: six- to nine-month follow-ups
von Buedingen et al. BMC Family Practice  (2018) 19:131 Page 6 of 11
Ta
b
le
3
M
ed
ic
at
io
n
ch
an
ge
s
at
pa
tie
nt
le
ve
l
Δ
1
(b
as
el
in
e
to
6-
m
on
th
fo
llo
w
-u
p)
Δ
2
(6
-m
on
th
fo
llo
w
-u
p
to
9-
m
on
th
fo
llo
w
-u
p)
In
te
rv
en
tio
n
gr
ou
p
(IG
)
(n
=
25
2)
C
on
tr
ol
gr
ou
p
(C
G
)
(n
=
25
0)
To
ta
l
(N
=
50
2)
Pr
op
or
tio
n
di
ffe
re
nc
e
IG
vs
.C
G
(9
5%
C
I)
In
te
rv
en
tio
n
gr
ou
p
(IG
)
(n
=
25
2)
C
on
tr
ol
gr
ou
p
(C
G
)
(n
=
25
0)
To
ta
l
(N
=
50
2)
Pr
op
or
tio
n
di
ffe
re
nc
e
IG
vs
.C
G
(9
5%
C
I)
A
PI A
dd
iti
on
16
0
(6
3%
)
15
3
(6
1%
)
31
3
(6
2%
)
0.
02
(−
0.
07
;0
.1
1)
P
=
0.
66
1
93
(3
7%
)
88
(3
5%
)
18
1
(3
6%
)
0.
02
(−
0.
07
;0
.1
1)
P
=
0.
76
1
D
is
co
nt
in
ua
tio
n
17
6
(7
0%
)
16
1
(6
4%
)
33
7
(6
7%
)
0.
05
(−
0.
03
;0
.1
4)
P
=
0.
22
9
11
9
(4
7%
)
12
9
(5
2%
)
24
8
(4
9%
)
−
0.
04
(−
0.
14
;0
.0
5)
P
=
0.
37
3
In
tr
ac
la
ss
su
bs
tit
ut
io
n
23
(9
%
)
18
(7
%
)
41
(8
.2
%
)
0.
02
(−
0.
03
;0
.0
7)
P
=
0.
53
2
14
(6
%
)
7
(3
%
)
21
(4
%
)
0.
03
(−
0.
01
;0
.0
7)
,P
=
0.
18
7
Re
st
ar
t
of
pr
ev
io
us
ly
di
sc
on
tin
ue
d
dr
ug
s
–
–
–
n.
a.
51
/1
76
(2
9%
)
53
/1
61
(3
0%
)
10
4/
33
7
(3
1%
)
−
0.
01
(−
0.
08
;0
.0
7)
,P
=
0.
87
6
St
re
ng
th
of
th
e
A
PI
In
cr
ea
se
46
(1
8%
)
36
(1
4%
)
82
(1
6%
)
0.
04
(−
0.
03
;0
.1
1)
P
=
0.
29
5
45
(1
8%
)
35
(1
4%
)
80
(1
6%
)
0.
04
(−
0.
03
;0
.1
1)
,P
=
0.
29
D
ec
re
as
e
44
(1
7%
)
49
(2
0%
)
93
(1
9%
)
−
0.
02
(−
0.
09
;0
.0
5)
,P
=
0.
61
6
31
(1
2%
)
37
(1
5%
)
70
(1
4%
)
−
0.
02
(−
0.
09
;0
.0
4)
,P
=
0.
49
2
D
os
ag
e
D
ai
ly
do
sa
ge
in
cr
ea
se
91
(3
6%
)
80
(3
2%
)
17
1
(3
4%
)
0.
04
(−
0.
05
;0
.1
3)
,P
=
0.
38
67
(2
7%
)
61
(2
4%
)
12
8
(2
6%
)
0.
02
(−
0.
06
;0
.1
),
P
=
0.
64
6
D
ai
ly
do
sa
ge
de
cr
ea
se
10
6
(4
2%
)
79
(3
2%
)
18
5
(3
7%
)
0.
1
(0
.0
2;
0.
19
),
P
=
0.
01
9*
72
(2
9%
)
58
(2
3%
)
13
0
(2
6%
)
0.
05
(−
0.
03
;0
.1
3)
,P
=
0.
20
3
A
pp
lic
at
io
n
in
te
rv
al
sh
or
te
ne
d
55
(2
2%
)
42
(1
7%
)
97
(1
9%
)
0.
05
(−
0.
02
;0
.1
2)
,P
=
0.
18
9
32
(1
3%
)
20
(8
%
)
52
(1
0%
)
0.
05
(−
0.
01
;0
.1
),
P
=
0.
11
4
A
pp
lic
at
io
n
in
te
rv
al
pr
ol
on
ge
d
48
(1
9%
)
35
(1
4%
)
83
(1
7%
)
0.
05
(−
0.
02
;0
.1
2)
,P
=
0.
16
1
28
(1
1%
)
26
(1
0%
)
54
(1
1%
)
0.
01
(−
0.
05
;0
.0
7)
,P
=
0.
91
C
ha
ng
e
in
ap
pl
ic
at
io
n
tim
e
po
in
t
14
5
(5
8%
)
15
5
(6
2%
)
30
0
(6
0%
)
−
0.
04
(−
0.
13
;0
.0
5)
,P
=
0.
35
3
98
(3
9%
)
11
8
(4
7%
)
21
6
(4
5%
)
−
0.
08
(−
0.
17
;0
.0
1)
,P
=
0.
07
3
Pi
ll
sp
lit
tin
g
st
ar
te
d
43
(1
7%
)
35
(1
4%
)
78
(1
6%
)
0.
03
(−
0.
04
;0
.1
),
P
=
0.
41
23
(9
%
)
19
(8
%
)
42
(8
%
)
0.
02
(−
0.
04
;0
.0
7)
,P
=
0.
64
8
Pi
ll
sp
lit
tin
g
st
op
pe
d
30
(1
2%
)
35
(1
4%
)
65
(1
3%
)
−
0.
02
(−
0.
08
;0
.0
4)
,P
=
0.
57
1
13
(5
%
)
18
(7
%
)
31
(6
%
)
−
0.
02
(−
0.
07
;0
.0
3)
,P
=
0.
44
5
A
dm
in
is
tr
at
io
n
m
et
ho
d
C
ha
ng
e
in
ad
m
in
is
tr
at
io
n
m
et
ho
d
47
(1
9%
)
32
(1
3%
)
79
(1
6%
)
0.
06
(−
0.
01
;0
.1
3)
,P
=
0.
09
3
37
(1
5%
)
42
(1
7%
)
79
(1
6%
)
−
0.
02
(−
0.
09
;0
.0
5)
,P
=
0.
59
7
A
PI
ac
tiv
e
ph
ar
m
ac
eu
tic
al
in
gr
ed
ie
nt
*D
iff
er
en
ce
be
tw
ee
n
in
te
rv
en
tio
n
gr
ou
p
an
d
co
nt
ro
lg
ro
up
w
as
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
von Buedingen et al. BMC Family Practice  (2018) 19:131 Page 7 of 11
least one discontinuation and the average was 4.2 per
patient [53]. In studies conducted in nursing homes,
drugs were withdrawn in 59% [55] and 63% [56] of pa-
tients (on average 4.4 and 2.8 per patient respectively).
However, no other medication changes were reported in
these studies.
Strengths & Limitations
The robust design of the pragmatic cluster-randomised
controlled PRIMUM trial was a major strength. This is
particularly reflected in the random sample of patients per
practice, the collection of primary data, the quality assu-
rance and validation of medication data, the stepwise deve-
lopment and forward-backward validation of the algorithm
to explore medication changes and its application by two
independent researchers. This allowed a rich exploratory
approach to the number and pattern of medication changes
in older patients with multimorbidity and polypharmacy
and the extension of the algorithm provided by Lam et al.
to include the patient’s perspective [20]. However, the study
design was also a limitation because the intention of the
intervention was to identify and change inappropriate
medication regimens. The vast majority of patients
included in the PRIMUM study received appropriate
prescriptions according to the Medication Appropriateness
Index (MAI) [57] and reported good quality of life and
functional status. The intervention had no effect on pri-
mary and secondary outcomes [32], but medication
changes did slightly increase (according to the multivariate
model, 19% more frequently in the intervention group, with
slightly more dosage reductions). The MAI does not reli-
ably detect underuse [58] and our ratings may have missed
also inappropriateness. Furthermore, the PRIMUM study
included three measuring points over a period of nine
months, which resulted in a series of cross-sectional
measurements rather than continuous documentation, so
we may have missed a number of medication changes
between study visits and our results may therefore be rather
conservative.
Implication
Our results illustrate that medication regimens in older
patients with multimorbidity and polypharmacy are rela-
tively unstable, and this has major implications. Firstly,
future analyses should seek to discriminate appropriate
from inappropriate, planned vs. ad hoc changes and
examine changes in high-risk drugs, as these are more
likely to be clinically significant for patients [59]. For cli-
nicians and patients, it is of interest whether frequent
medication changes increase longitudinal complexity
and whether this affects patient adherence and health
care costs in developing strategies to avoid unnecessary
alterations in medication regimens in elderly, chronically
ill patients with multimorbidity. Secondly, our findings
pose fundamental methodological questions with respect
to polypharmacy studies (no matter whether observational
Table 4 Most frequently changed drugs
Interval Δ1 (baseline to 6 month follow-up) Interval Δ2 (6-month follow-up to 9-month follow-up)
Intervention group Control group Intervention group Control group
Drug Changes in Δ1 /
total prescriptions
at T0a
(n / N, %)
Drug Changes in Δ1 /
total prescriptions
at T0a
(n / N, %)
Drug Changes in Δ2 /
total prescriptions
at T1a
(n / N, %)
Drug Changes in Δ2 /
total prescriptions
at T1a
(n / N, %)
Simvastatin 75 / 104 (72%) Simvastatin 90 / 128 (70%) Aspirin* 40 / 108 (37%) Simvastatin 72 / 121 (60%)
Ramipril 70 / 67 (104%) Aspirin* 58 / 126 (46%) Omeprazole 39 / 48 (81%) Aspirin* 50 / 122 (41%)
Metformin 63 / 61 (103%) Metformin 49 / 57 (86%) Simvastatin 38 / 107 (35%) Metformin 39 / 50 (78%)
Amlodipine 63 / 76 (83%) Allopurinol 43 / 47 (91%) Ramipril 37 / 64 (56%) Omeprazole 34 / 52 (65%)
Metoprolol* 59 / 69 (85%) Amlodipine 40 / 57 (70%) Metformin 34 / 60 (57%) Torasemide 33 / 50 (66%)
Bisoprolol 58 / 62 (93%) Pantoprazole 39 / 33 (118%) Torasemide 34 / 57 (60%) Metoprolol* 31 / 49 (63%)
Omeprazole 54 / 55 (98%) Bisoprolol 39 / 65 (60%) Pantoprazole 29 / 31 (93%) Ramipril 29 / 58 (50%)
Aspirin* 53 / 105 (50%) Metoprolol* 38 / 54 (70%) Allopurinol 28 / 44 (64%) Pantoprazole 28 / 29 (96%)
Torasemide 45 / 52 (87%) Ramipril 38 / 54 (70%) Metoprolol* 27 / 67 (40%) Amlodipine 25 / 53 (47%)
Allopurinol 45 / 53 (85%) Omeprazole 37 / 50 (74%) Amlodipine 25 / 70 (36%) Bisoprolol 24 / 62 (39%)
Levothyroxine 40 / 55 (73%) Torasemide 37 / 55 (67%) Bisoprolol 18 / 63 (29%) Allopurinol 23 / 44 (52%)
Pantoprazole 37 / 30 (123%) HCT 24 / 40 (60%) Diclofenac 17 / 34 (50%) Diclofenac 22 / 12 (183%)
Diclofenac 33 / 36 (92%) Levothyroxine 23 / 55 (42%) Ca + D3 16 / 14 (114%) HCT 20 / 37 (54%)
†number of changed prescriptions during the interval per number of prescriptions at the begin of the interval, percentages > 100% indicate prescriptions with
more than one change during the interval under investigation. API – active pharmaceutical ingredient, Aspirin* - low dose aspirin, Ca + D3 – combination of
calcium and cholecalciferol (vitamin D3), HCT – hydrochlorothiazide, Metoprolol* - metoprolol-succinate
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or interventional): how reliable are cross-sectional mea-
surements of medication in this population, and what are
suitable measurement intervals? Future studies should as-
sess longitudinal changes so that researchers in the field
can select appropriate study intervals.
Conclusion
Medication regimens in older patients with multimorbidity
and polypharmacy change frequently. Most of the changes
are discontinuations and dosage alterations followed by
additional prescriptions and restarts. Modifications also
include drugs, such as statins and low-dose aspirins, that are
intended for prescription in relatively fixed dosages in the
treatment of chronic conditions. These findings cast doubt
on the effectiveness of cross-sectional assessments of medi-
cation (appropriateness) and support longitudinal assess-
ments where possible. Dedicated future studies should
longitudinally assess changes in medication regimens and
seek to explain them. They should also study their effect on
patient adherence.
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